TY - JOUR
T1 - Minimal clinically important change in patients with cervical dystonia
T2 - Results from the CD PROBE study
AU - Dashtipour, Khashayar
AU - Mari, Zoltan
AU - Jankovic, Joseph
AU - Adler, Charles H.
AU - Schwartz, Marc
AU - Brin, Mitchell F.
N1 - Funding Information:
This study was sponsored by Allergan plc, Dublin, Ireland. Writing and editorial assistance was provided to the authors by Cindy Taylor, PhD, Dana Franznick, PharmD, and Lee Hohaia, PharmD, of Complete Healthcare Communications, LLC (North Wales, PA), a CHC Group company, and funded by Allergan plc, Dublin, Ireland. All authors met the ICMJE authorship criteria. Neither honoraria nor payments were made for authorship.Dr. Dashtipour has received honoraria for consulting, advisory services or speaking services from AbbVie, Acadia, Neurocrine, Sunovion, Teva, Impax, IPSEN, Allergan plc, Lundbeck, Merz, and US World Meds. Dr. Mari has received research grant support from NIH, MJFF, NPF, AbbVie, and AVID. Dr. Jankovic has received grant support from Adamas Pharmaceuticals, Inc., Allergan plc, CHDI Foundation, Civitas/Acorda Therapeutics, Dystonia Medical Research Foundation, Kyowa Haako Kirin Pharma, Inc., Lundbeck, Inc., Medtronic, Merz Pharmaceuticals, Michael J. Fox Foundation for Parkinson Research, National Institutes of Health, Parkinson's Foundation, Parkinson Study Group, Pfizer, Prothena Biosciences, Inc., Psyadon Pharmaceuticals, Inc., Revance Therapeutics, Inc., St. Jude Medical, and Teva Pharmaceutical Industries, Ltd. He has served as a consultant or as an advisory committee member for Adamas Pharmaceuticals, Inc., Allergan plc, and Teva Pharmaceutical Industries, Ltd. Dr. Adler has received research funding from Avid, Michael J. Fox Foundation, and NIH, and consulting fees from Acadia, Adamas, Cynapsus, Jazz, Lundbeck, Merz, Neurocrine, and Sunovion. Mr. Schwartz is the founder of MS Biostatistics, LLC, and was formerly an employee of MedNet Solutions Inc., which was contracted by Allergan to provide biostatistical services for the study. Dr. Brin is an employee of Allergan plc and receives stock in the company. Writing and editorial assistance was provided to the authors by Lee Hohaia, PharmD, of Complete Healthcare Communications, LLC (North Wales, PA), Cindy Taylor, PhD, and Dana Franznick, PharmD, and funded by Allergan plc (Dublin, Ireland). All authors met the ICMJE authorship criteria. Neither honoraria nor payments were made for authorship.
Funding Information:
This study was sponsored by Allergan plc , Dublin, Ireland. Writing and editorial assistance was provided to the authors by Cindy Taylor, PhD, Dana Franznick, PharmD, and Lee Hohaia, PharmD, of Complete Healthcare Communications, LLC (North Wales, PA) , a CHC Group company, and funded by Allergan plc , Dublin, Ireland. All authors met the ICMJE authorship criteria. Neither honoraria nor payments were made for authorship.
Publisher Copyright:
© 2019 The Authors
PY - 2019/10/15
Y1 - 2019/10/15
N2 - Objective: To determine the minimal clinically important change (MCIC) on Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scores using data from Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE), which captured real-world practices and outcomes. Methods: Changes in the baseline TWSTRS scores (point and percentage changes) were compared to changes in the Patient and Clinician Global Impression of Change (PGIC and CGIC) ratings. Using logistic regression, the discrimination of the model was determined. Results: Among the 479 patients who completed all TWSTRS assessments, the mean TWSTRS Total score significantly decreased from baseline (39.2) to the final visit (27.1) (P <.0001). TWSTRS Total score point changes that compared with PGIC assessments “very much improved,” “much improved” or better, and “minimally improved” or better were −11, −9, and −8, respectively, and were similar to previously published changes (ie, a decrease of ≥10 points). TWSTRS Total score data met indicators of good cutoffs for discrimination of the model including ≥70% percentage of outcomes correctly classified when compared with PGIC ratings. The TWSTRS Total score mapped to PGIC and CGIC ratings better than any TWSTRS subscale score. Conclusions: The MCIC for improvement was ≥8 points based on mean TWSTRS Total scores in patients with cervical dystonia when compared against the patient-based evaluation of benefit (PGIC).
AB - Objective: To determine the minimal clinically important change (MCIC) on Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scores using data from Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE), which captured real-world practices and outcomes. Methods: Changes in the baseline TWSTRS scores (point and percentage changes) were compared to changes in the Patient and Clinician Global Impression of Change (PGIC and CGIC) ratings. Using logistic regression, the discrimination of the model was determined. Results: Among the 479 patients who completed all TWSTRS assessments, the mean TWSTRS Total score significantly decreased from baseline (39.2) to the final visit (27.1) (P <.0001). TWSTRS Total score point changes that compared with PGIC assessments “very much improved,” “much improved” or better, and “minimally improved” or better were −11, −9, and −8, respectively, and were similar to previously published changes (ie, a decrease of ≥10 points). TWSTRS Total score data met indicators of good cutoffs for discrimination of the model including ≥70% percentage of outcomes correctly classified when compared with PGIC ratings. The TWSTRS Total score mapped to PGIC and CGIC ratings better than any TWSTRS subscale score. Conclusions: The MCIC for improvement was ≥8 points based on mean TWSTRS Total scores in patients with cervical dystonia when compared against the patient-based evaluation of benefit (PGIC).
KW - CD PROBE
KW - Cervical dystonia
KW - Clinical effectiveness
KW - OnabotulinumtoxinA
UR - http://www.scopus.com/inward/record.url?scp=85071716511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071716511&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2019.07.031
DO - 10.1016/j.jns.2019.07.031
M3 - Article
C2 - 31494402
AN - SCOPUS:85071716511
SN - 0022-510X
VL - 405
JO - Journal of the neurological sciences
JF - Journal of the neurological sciences
M1 - 116413
ER -